Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-Anti-ED-B mAbs SPECT Imaging in Solid Tumors
NCT05623891Phase 1Unknown
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-B5-IgG4 in solid tumor, sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Evaluation of tissue distribution of 177Lu-Anti-ED-B mAbs(B5-IgG4) at 1 year, Dosimetry estimates of 177Lu-Anti-ED-B mAbs(B5-IgG4) at 1 year and 1 more. Status: unknown.
02
Drugs
177Lu-B5-IgG4
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05623891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623891.